Citation Information :
Venkata PK, Bolla D, Donthu RK. Intravenous Ketamine as an Adjunctive Treatment for Dysthymia: A Case Report. Ind J Priv Psychiatry 2024; 18 (2):94-95.
Background: Dysthymia, characterized by persistent low mood without reaching the severity of depression, poses a challenge in terms of prolonged symptom duration and limited response to conventional antidepressant therapies.
Case description: This case report details the presentation of a patient with dysthymia inadequately responding to antidepressant treatments. Intravenous ketamine was given as an adjunctive treatment, resulting in significant clinical improvement.
Conclusion and clinical significance: Our findings suggest that ketamine could serve as a beneficial adjunct in the treatment of dysthymia. However, it is noteworthy that sustained efficacy may necessitate frequent infusions, ideally at intervals of at least 2 weeks. Further research is warranted to validate and expand upon these observations, offering new insights into the potential role of ketamine in the management of dysthymia.
Griffiths J, Ravindran AV, Merali Z, et al. Dysthymia: A review of pharmacological and behavioral factors. Mol Psychiatry 2000;5(3):242–261. DOI: 10.1038/sj.mp.4000697.
World Health Organization. The ICD-10 Classification of Mental and Behavioural Disorders. Geneve, Switzerland: World Health Organization, 1993.
Ishizaki J, Mimura M. Dysthymia and apathy: Diagnosis and treatment. Depress Res Treat 2011;2011:893905. DOI: 10.1155/2011/893905.
Rosenbaum SB, Gupta V, Patel P, et al. Ketamine. In: StatPearls. Treasure Island (FL): StatPearls Publishing. Available at: http://www.ncbi.nlm.nih.gov/books/NBK470357/. Accessed on: 10 November 2023.
Andrade C. Ketamine for depression, 4: In what dose, at what rate, by what route, for how long, and at what frequency? J Clin Psychiatry 2017;78:e852–e857. DOI: 10.4088/JCP.17f11738.
Zanos P, Gould TD. Mechanisms of ketamine action as an antidepressant. Mol Psychiatry 2018;23(4):801–811. DOI: 10.1038/mp.2017.255.
Nikolin S, Rodgers A, Schwaab A, et al. Ketamine for the treatment of major depression: A systematic review and meta-analysis. EClinicalMedicine 2023;62:102127. DOI: 10.1016/j.eclinm.2023.102127.
Marcantoni WS, Akoumba BS, Wassef M, et al. A systematic review and meta-analysis of the efficacy of intravenous ketamine infusion for treatment resistant depression. January 2009–January 2019. J Affect Disord 2020;277:831–841. DOI: 10.1016/j.jad.2020.09.007.
Krystal JH, Karper LP, Seibyl JP, et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 1994;51(3):199–214. DOI: 10.1001/archpsyc.1994.03950030035004.
Zarate CA Jr, Singh JB, Carlson PJ, et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 2006;63(8):856–864. DOI: 10.1001/archpsyc.63.8.856.
Loo CK, Gálvez V, O'Keefe E, et al. Placebo-controlled pilot trial testing dose titration and intravenous, intramuscular and subcutaneous routes for ketamine in depression. Acta Psychiatr Scand 2016;134(1):48–56. DOI: 10.1111/acps.12572.
Berman RM, Cappiello A, Anand A, et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 2000;47(4):351–354. DOI: 10.1016/s0006-3223(99)00230-9.
